# CVS Health CDR (CAD Hedged) (CVS.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: Healthcare / Health Care Providers. Price C$21.79, market value C$153.1 billion.

## Valuation
- **P/E (trailing): 23.9×** (5-yr avg 75.1×, 3-yr avg 75.1×). CVS Health CDR (CAD Hedged) trades at 23.9× trailing earnings, well below its own five-year average of 75.1×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 0.4×**. Each dollar of revenue is priced at 0.4×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 16.6×**. Enterprise value is 16.6× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 7.7%** (5-yr avg 5.9%). Free cash flow equals 7.7% of the market value, above its five-year average of 5.9%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 4.2%**. The inverse of the P/E: 4.2% of the price is earned each year.

## Profitability
- **Gross margin: 14.2%**. CVS Health CDR (CAD Hedged) keeps 14.2% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: 3.4%**. 3.4% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 0.4%**. 0.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 2.4%**. 2.4% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 8.2%**. Return on all capital, debt included, is 8.2%.
- **Return on assets: 1.9%**. Each dollar of assets produces 1.9% of profit.

## Growth
- **Revenue growth (1 yr): 7.8%** (3-yr 7.6%/yr). Revenue grew 7.8% over the last year.
- **EPS growth (1 yr): -62.0%** (3-yr -24.7%/yr). Earnings per share fell 62.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -16.6%/yr**. Free cash flow has compounded at -16.6% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 1.06**. Debt is 1.06 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 5.2×**. It would take 5.2 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: 4.5×**. Operating profit covers interest 4.5× over, a safe margin.
- **Current ratio: 0.84** (quick 0.63). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 2.58**. A Z-score of 2.58 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. CVS Health CDR (CAD Hedged) does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -17.6%** (29.4% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.03** (volatility 33%). Beta of 0.03 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CVS.TO · Page: https://foliofundamentals.com/stocks/cvs.to

Not investment advice.